Overall HSTO gets a fundamental rating of 3 out of 10. We evaluated HSTO against 530 industry peers in the Biotechnology industry. HSTO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HSTO is quite expensive at the moment. It does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.51% | ||
| ROE | -130.43% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19836.8% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.61 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.54 | ||
| Quick Ratio | 8.54 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.658
+0.15 (+29.27%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 147.88 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.3 | ||
| P/tB | 0.3 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.51% | ||
| ROE | -130.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19836.8% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 52.63% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.54 | ||
| Quick Ratio | 8.54 | ||
| Altman-Z | -11.61 |
ChartMill assigns a fundamental rating of 3 / 10 to HSTO.
ChartMill assigns a valuation rating of 0 / 10 to HISTOGEN INC (HSTO). This can be considered as Overvalued.
HISTOGEN INC (HSTO) has a profitability rating of 1 / 10.
The Earnings per Share (EPS) of HISTOGEN INC (HSTO) is expected to grow by 26.45% in the next year.